Therefore, other metabolically modifiable agents, including classic insulin sensitizers (thiazolidinediones) and non-classical insulin sensitivity-improving drugs (acarbose, sodium-glucose cotransporter (SGLT2) inhibitors, glucagon-like-peptide 1 receptor agonist (GLP-1RA)), are also indicated and effective in PCOS patients. The gene discussed is INS; the disease is polycystic ovary syndrome.